IS6039A - Tálmi við súlfamatóhýdroxamsýrumálmprótínkljúfi - Google Patents
Tálmi við súlfamatóhýdroxamsýrumálmprótínkljúfiInfo
- Publication number
- IS6039A IS6039A IS6039A IS6039A IS6039A IS 6039 A IS6039 A IS 6039A IS 6039 A IS6039 A IS 6039A IS 6039 A IS6039 A IS 6039A IS 6039 A IS6039 A IS 6039A
- Authority
- IS
- Iceland
- Prior art keywords
- sulfamato
- inhibition
- acid metal
- hydroxamic acid
- protein cleavage
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11918199P | 1999-02-08 | 1999-02-08 | |
PCT/US2000/003061 WO2000046221A1 (en) | 1999-02-08 | 2000-02-07 | Sulfamato hydroxamic acid metalloprotease inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
IS6039A true IS6039A (is) | 2001-08-07 |
Family
ID=22382974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS6039A IS6039A (is) | 1999-02-08 | 2001-08-07 | Tálmi við súlfamatóhýdroxamsýrumálmprótínkljúfi |
Country Status (27)
Country | Link |
---|---|
US (3) | US6448250B1 (is) |
EP (1) | EP1157021A1 (is) |
JP (1) | JP2002536373A (is) |
KR (1) | KR20010102000A (is) |
CN (1) | CN1216056C (is) |
AP (1) | AP2001002240A0 (is) |
AR (1) | AR036585A1 (is) |
AU (1) | AU775701B2 (is) |
BG (1) | BG105788A (is) |
BR (1) | BR0008440A (is) |
CA (1) | CA2362230A1 (is) |
CZ (1) | CZ20012849A3 (is) |
EA (1) | EA005500B1 (is) |
EE (1) | EE200100410A (is) |
GE (1) | GEP20043238B (is) |
HK (1) | HK1049660B (is) |
HR (1) | HRP20010660A2 (is) |
HU (1) | HUP0200119A3 (is) |
IL (1) | IL144783A0 (is) |
IS (1) | IS6039A (is) |
MX (1) | MXPA01007987A (is) |
NO (1) | NO20013850L (is) |
PL (1) | PL350193A1 (is) |
SK (1) | SK11352001A3 (is) |
WO (1) | WO2000046221A1 (is) |
YU (1) | YU57101A (is) |
ZA (1) | ZA200106492B (is) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6747027B1 (en) | 1996-07-22 | 2004-06-08 | Pharmacia Corporation | Thiol sulfonamide metalloprotease inhibitors |
US7115632B1 (en) | 1999-05-12 | 2006-10-03 | G. D. Searle & Co. | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
US6696449B2 (en) | 1997-03-04 | 2004-02-24 | Pharmacia Corporation | Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors |
US6794511B2 (en) | 1997-03-04 | 2004-09-21 | G. D. Searle | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
US20010039287A1 (en) * | 1997-11-14 | 2001-11-08 | Thomas E Barta | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
RU2250105C2 (ru) | 1997-11-14 | 2005-04-20 | Дж.Д.Сёрл ЛЛС | Ароматическая сульфонгидроксамовая кислота в качестве ингибитора металлопротеаз |
US6750228B1 (en) | 1997-11-14 | 2004-06-15 | Pharmacia Corporation | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
US6800646B1 (en) | 1999-02-08 | 2004-10-05 | Pharmacia Corporation | Sulfamato hydroxamic acid metalloprotease inhibitor |
US6511993B1 (en) | 1999-06-03 | 2003-01-28 | Kevin Neil Dack | Metalloprotease inhibitors |
US6683093B2 (en) | 2000-05-12 | 2004-01-27 | Pharmacia Corporation | Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
EA200301116A1 (ru) | 2001-05-11 | 2004-06-24 | Фармация Корпорейшн | Гидроксаматы ароматических сульфонов и их применение в качестве ингибиторов протеаз |
US6683078B2 (en) | 2001-07-19 | 2004-01-27 | Pharmacia Corporation | Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
GB0119474D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
GB0119396D0 (en) * | 2001-08-09 | 2001-10-03 | Celltech R&D Ltd | Hydroxamic acid derivatives |
CA2479906C (en) | 2002-04-03 | 2011-02-08 | Topotarget Uk Limited | Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors |
JP2005537228A (ja) | 2002-04-25 | 2005-12-08 | ファルマシア・コーポレーション | ピペリジニル−及びピペラジニル−スルホニルメチルヒドロキサム酸並びにプロテアーゼ阻害剤としてのその使用 |
US20050209278A1 (en) * | 2002-04-25 | 2005-09-22 | Mcdonald Joseph J | Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
BR0312036A (pt) * | 2002-06-25 | 2005-04-05 | Pharmacia Corp | ácido arilsulfonilhidroxâmico e derivados de amida bem como composição farmacêutica contendo os mesmos e uso dos mesmos |
GB0216382D0 (en) * | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Compounds |
MXPA05005474A (es) * | 2002-11-25 | 2005-07-25 | Pharmacia Corp | Acidos y amidas heteroarilsulfonilmetil hidroxamicos y su uso como inhibidores de proteasas. |
ATE457716T1 (de) | 2002-12-30 | 2010-03-15 | Angiotech Int Ag | Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung |
JP4612621B2 (ja) | 2003-01-17 | 2011-01-12 | トポターゲット ユーケー リミテッド | Hdac阻害剤としてのエステル又はケトン結合を含むカルバミン酸化合物 |
US20050043533A1 (en) * | 2003-03-25 | 2005-02-24 | Babiak Kevin A. | Process for making alpha-substituted hydroxamic acids |
GB0319069D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Therapeutically useful compounds |
EP1743638A1 (en) | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | Pharmaceutical formulations of substituted pyrazoline compounds |
EP1963261A1 (en) * | 2005-12-21 | 2008-09-03 | Decode Genetics EHF | Biaryl substituted nitrogen containing heterocycle inhibitors of lta4h for treating inflammation |
US8399485B2 (en) | 2006-12-14 | 2013-03-19 | Merck Sharp & Dohme Corp. | Acyl bipiperidinyl compounds useful as GPR 119 agonists |
US8906334B2 (en) | 2007-05-14 | 2014-12-09 | Invista North America S.A R.L. | High efficiency reactor and process |
WO2013039851A1 (en) | 2011-09-12 | 2013-03-21 | Mallinckrodt Llc | Optical agents for imaging and visualization of matrix metalloproteinase enzymes |
WO2018037254A1 (en) * | 2016-08-24 | 2018-03-01 | Tfchem | Difluorinated compounds as depigmenting or lightening agents |
WO2020006384A1 (en) | 2018-06-29 | 2020-01-02 | Loyola University Of Chicago | Carborane hydroxamic acid matrix metalloproteinase inhibitors and agents for boron neutron capture therapy |
EP3860608A1 (en) | 2018-10-04 | 2021-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1067965A (en) | 1912-10-31 | 1913-07-22 | C T Ham Mfg Company | Vehicle-lamp. |
GB1067965A (en) * | 1965-01-22 | 1967-05-10 | Beecham Group Ltd | Penicillins, esters, amides and salts thereof |
US4595700A (en) | 1984-12-21 | 1986-06-17 | G. D. Searle & Co. | Thiol based collagenase inhibitors |
US4882434A (en) | 1986-10-29 | 1989-11-21 | Takeda Chemical Industries, Ltd. | Gamma-lactonecarboxylic acid derivatives and their use as antibacterial agents or intermediates |
DE3811777A1 (de) * | 1988-04-08 | 1989-10-19 | Hoechst Ag | Heterocyclisch substituierte alkyl- und alkenylsulfonylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als herbizide oder pflanzenwachstumsregulatoren |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
JP3122161B2 (ja) | 1991-05-16 | 2001-01-09 | 武田薬品工業株式会社 | γ−ラクトン免疫抑制剤 |
EP0634998B1 (en) | 1992-04-07 | 1997-03-19 | British Biotech Pharmaceuticals Limited | Hydroxamic acid based collagenase and cytokine inhibitors |
US5376664A (en) | 1992-07-27 | 1994-12-27 | The Du Pont Merck Pharmaceutical Company | Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agents |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
GB9307956D0 (en) | 1993-04-17 | 1993-06-02 | Walls Alan J | Hydroxamic acid derivatives |
GB9320660D0 (en) | 1993-10-07 | 1993-11-24 | British Bio Technology | Inhibition of cytokine production |
DE69420859T2 (de) | 1993-11-04 | 2000-01-05 | The Liposome Co.,Inc. | Multilamellare liposomformulierungen, die einen arachidsäuremetaboliten enthalten |
GB9323165D0 (en) | 1993-11-10 | 1994-01-05 | Chiros Ltd | Compounds |
GB9416897D0 (en) | 1994-08-20 | 1994-10-12 | British Biotech Pharm | Metalloproteinase inhibitors |
DE69509401T2 (de) | 1994-10-05 | 1999-08-19 | Darwin Discovery Ltd. | Peptidische verbindungen und deren therapeutische verwendung als metalloproteinase-inhibitoren |
TR199800990T2 (xx) | 1995-12-08 | 1998-07-21 | Agouron Pharmaceuticals, Inc. | Metaloproteinaz inhibit�rleri, bunlar� i�eren farmas�tik bile�imler, bunlar�n farmas�tik kullan�mlar� ve bunlar�n �retiminde kullan�labilecek y�ntemler ve ara �r�nler. |
PT780386E (pt) | 1995-12-20 | 2003-02-28 | Hoffmann La Roche | Inibidores de metaloprotease de matriz |
PT871439E (pt) | 1996-01-02 | 2004-08-31 | Aventis Pharma Inc | Compostos do acido hidroxamico substituidos (arilo heteroarilo arilmetilo ou heteroarilmetilo) |
ES2225980T3 (es) * | 1996-06-20 | 2005-03-16 | Schering Corporation | Naftridinas que afectan al receptor de il-4 y al g-csf. |
ZA98376B (en) * | 1997-01-23 | 1998-07-23 | Hoffmann La Roche | Sulfamide-metalloprotease inhibitors |
DK0970046T3 (da) | 1997-02-27 | 2004-04-13 | Wyeth Corp | N-Hydroxy-2-(alkyl-, aryl- eller heteroarylsulfanyl, -sulfinyl eller -sulfonyl)-3-substituerede alkyl- eller heteroaryl-amider som matrixmetalloproteinaseinhibitorer |
CA2308359A1 (en) | 1997-11-12 | 1999-05-20 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
US20010039287A1 (en) | 1997-11-14 | 2001-11-08 | Thomas E Barta | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
RU2250105C2 (ru) * | 1997-11-14 | 2005-04-20 | Дж.Д.Сёрл ЛЛС | Ароматическая сульфонгидроксамовая кислота в качестве ингибитора металлопротеаз |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
IL127496A0 (en) | 1997-12-19 | 1999-10-28 | Pfizer Prod Inc | The use of MMP inhibitors for the treatment of ocular angiogenesis |
GB9801690D0 (en) * | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
HUP0101837A3 (en) | 1998-02-19 | 2001-11-28 | American Cyanamid Co Madison | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
CN1346282A (zh) | 1998-12-23 | 2002-04-24 | G.D.西尔公司 | 在肿瘤的治疗中使用环加氧酶-2-抑制剂与一种或多种抗肿瘤剂作为联合治疗的方法 |
-
2000
- 2000-02-07 GE GEAP20006101A patent/GEP20043238B/en unknown
- 2000-02-07 AP APAP/P/2001/002240A patent/AP2001002240A0/en unknown
- 2000-02-07 KR KR1020017010040A patent/KR20010102000A/ko not_active Application Discontinuation
- 2000-02-07 EA EA200100867A patent/EA005500B1/ru not_active IP Right Cessation
- 2000-02-07 EP EP00905996A patent/EP1157021A1/en not_active Withdrawn
- 2000-02-07 HU HU0200119A patent/HUP0200119A3/hu active IP Right Revival
- 2000-02-07 CA CA002362230A patent/CA2362230A1/en not_active Abandoned
- 2000-02-07 IL IL14478300A patent/IL144783A0/xx unknown
- 2000-02-07 EE EEP200100410A patent/EE200100410A/xx unknown
- 2000-02-07 SK SK1135-2001A patent/SK11352001A3/sk unknown
- 2000-02-07 AU AU27574/00A patent/AU775701B2/en not_active Ceased
- 2000-02-07 MX MXPA01007987A patent/MXPA01007987A/es unknown
- 2000-02-07 YU YU57101A patent/YU57101A/sh unknown
- 2000-02-07 BR BR0008440-9A patent/BR0008440A/pt not_active IP Right Cessation
- 2000-02-07 JP JP2000597291A patent/JP2002536373A/ja active Pending
- 2000-02-07 CN CN008060339A patent/CN1216056C/zh not_active Expired - Fee Related
- 2000-02-07 WO PCT/US2000/003061 patent/WO2000046221A1/en not_active Application Discontinuation
- 2000-02-07 PL PL00350193A patent/PL350193A1/xx not_active Application Discontinuation
- 2000-02-07 CZ CZ20012849A patent/CZ20012849A3/cs unknown
- 2000-02-07 US US09/499,276 patent/US6448250B1/en not_active Expired - Fee Related
- 2000-02-08 AR ARP000100538A patent/AR036585A1/es unknown
-
2001
- 2001-06-19 US US09/884,548 patent/US6372758B1/en not_active Expired - Fee Related
- 2001-08-07 BG BG105788A patent/BG105788A/bg unknown
- 2001-08-07 IS IS6039A patent/IS6039A/is unknown
- 2001-08-07 ZA ZA200106492A patent/ZA200106492B/en unknown
- 2001-08-07 NO NO20013850A patent/NO20013850L/no not_active Application Discontinuation
- 2001-09-07 HR HR20010660A patent/HRP20010660A2/hr not_active Application Discontinuation
-
2002
- 2002-02-26 US US10/084,713 patent/US6492367B1/en not_active Expired - Fee Related
-
2003
- 2003-02-07 HK HK03100924.8A patent/HK1049660B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2362230A1 (en) | 2000-08-10 |
MXPA01007987A (es) | 2002-04-24 |
HK1049660A1 (en) | 2003-05-23 |
NO20013850L (no) | 2001-09-19 |
CN1362954A (zh) | 2002-08-07 |
AU775701B2 (en) | 2004-08-12 |
CZ20012849A3 (cs) | 2002-05-15 |
HRP20010660A2 (en) | 2005-02-28 |
SK11352001A3 (sk) | 2002-09-10 |
NO20013850D0 (no) | 2001-08-07 |
PL350193A1 (en) | 2002-11-18 |
US6372758B1 (en) | 2002-04-16 |
EA005500B1 (ru) | 2005-02-24 |
BG105788A (bg) | 2002-02-28 |
EA200100867A1 (ru) | 2002-04-25 |
HK1049660B (zh) | 2006-05-12 |
AU2757400A (en) | 2000-08-25 |
EE200100410A (et) | 2002-12-16 |
CN1216056C (zh) | 2005-08-24 |
US6448250B1 (en) | 2002-09-10 |
JP2002536373A (ja) | 2002-10-29 |
AP2001002240A0 (en) | 2001-09-30 |
BR0008440A (pt) | 2002-03-26 |
HUP0200119A3 (en) | 2003-04-28 |
ZA200106492B (en) | 2003-05-07 |
WO2000046221A1 (en) | 2000-08-10 |
GEP20043238B (en) | 2004-05-25 |
HUP0200119A2 (en) | 2002-06-29 |
YU57101A (sh) | 2005-06-10 |
EP1157021A1 (en) | 2001-11-28 |
KR20010102000A (ko) | 2001-11-15 |
AR036585A1 (es) | 2004-09-22 |
US6492367B1 (en) | 2002-12-10 |
IL144783A0 (en) | 2002-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS6039A (is) | Tálmi við súlfamatóhýdroxamsýrumálmprótínkljúfi | |
NO20000877D0 (no) | Forbedret syrekorrosjonsinhibitor | |
MA26812A1 (fr) | Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases | |
PT1070069E (pt) | Derivados biciclicos do acido hidroxamico | |
DE69940306D1 (de) | Varianten der phytase | |
ATE269861T1 (de) | Substituierte indolalkansäure | |
DE69927969D1 (de) | Kontrollierte freisetzung von liponsäure | |
DK1100769T3 (da) | Aminomethylcarboxylsyrederivater | |
IS5735A (is) | Ný 3-arýl-2-hýdroxýprópínsýruafleiða III | |
NO981178L (no) | Vannl°selige korrosjonsinhibitorer | |
IL145411A0 (en) | Cleavage of nucleic acid from solid supports | |
IS5562A (is) | Nýjar díhýdroxýhexanósýru afleiður | |
FR2816843B1 (fr) | Inhibiteurs de l'enzyme 5 alpha-reductase | |
EE200100611A (et) | NOS inhibiitorite uued farmatseutilised kombinatsioonid | |
IT1313598B1 (it) | Dispersioni acquose di acidi percarbossilici | |
DE60016264D1 (de) | Direktmetallherstellung von teilen | |
ID28032A (id) | TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2 | |
DE60040524D1 (de) | Intein-vermittelte ligation von exprimierten proteinen | |
EE200000568A (et) | HIV-proteaasi inhibiitorite valmistamismeetod | |
ID25536A (id) | Metode pembuatan asam-asam 4-fenil-4-sianosikloheksanoat tersubstitusi | |
DK1228026T3 (da) | 15-Hydroxyicosatetraensyrerelaterede forbindelser og fremgangsmåde til anvendelse | |
DE69923255D1 (de) | Leucinaminopeptidase Gen | |
ATE227288T1 (de) | Acetylenische ortho-sulfonamido- und phosphinsäure-amido-bicyclische heteroarylhydroxamsäure als tace-inhibitoren | |
DE60336549D1 (de) | Hepatoprotektor aktivität von 2'-p-hydroxybenzoylmussaenosidsäure | |
PT1232141E (pt) | Eteres de o-desmetil-venlafaxina |